--- title: "What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch" type: "News" locale: "en" url: "https://longbridge.com/en/news/287440530.md" description: "Prosight Management increased its stake in Nektar Therapeutics by 180,367 shares, valued at approximately $10.27 million, reflecting a 1.68% change in its assets. The total value of its Nektar position rose by $29.43 million, with the firm holding 735,000 shares worth $52.88 million as of March 31, 2026. Nektar's stock has surged nearly 600% over the past year, and the company is preparing for a key Phase 3 trial for its treatment for autoimmune diseases." datetime: "2026-05-23T21:00:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/287440530.md) - [en](https://longbridge.com/en/news/287440530.md) - [zh-HK](https://longbridge.com/zh-HK/news/287440530.md) --- # What to Know About This Fund's $10 Million Nektar Bet Ahead of a Key Phase 3 Launch ## Key Points - Prosight Management increased its Nektar Therapeutics holding by 180,367 shares last quarter, an estimated $10.27 million buy based on average prices during the quarter. - The value of the firm’s Nektar Therapeutics position rose by $29.43 million in the quarter, reflecting both the share addition and stock price movement. - This transaction represented a 1.68% change in the fund’s 13F reportable assets under management. - After the trade, Prosight Management held 735,000 shares in Nektar Therapeutics, valued at $52.88 million as of March 31, 2026. - 10 stocks we like better than Nektar Therapeutics › On May 15, 2026, Prosight Management disclosed a buy of 180,367 shares of **Nektar Therapeutics** (NASDAQ:NKTR), an estimated $10.27 million trade based on quarterly average pricing. ## What happened According to a Securities and Exchange Commission (SEC) filing dated May 15, 2026, Prosight Management increased its position in Nektar Therapeutics by 180,367 shares. The estimated value of the additional shares is $10.27 million, calculated using the average closing price for the quarter ending March 31, 2026. The quarter-end value of the firm’s Nektar Therapeutics stake rose by $29.43 million, a figure that includes both trading activity and share price appreciation. ## What else to know - Prosight Management was a net buyer in Nektar Therapeutics this quarter. The post-trade stake accounted for 8.67% of its 13F reportable AUM. - Top five fund holdings after the filing: - NASDAQ: NKTR: $52.88 million (8.7% of AUM) - NYSE: BSX: $49.92 million (8.2% of AUM) - NASDAQ: JANX: $49.34 million (8.1% of AUM) - NASDAQ: PRCT: $48.64 million (8.0% of AUM) - NASDAQ: LKFT: $46.50 million (7.6% of AUM) - As of May 14, 2026, shares of Nektar Therapeutics were priced at $66.61, up nearly 600% over the past year and significantly outperforming the S&P 500, which is instead up about 28%. ## Company overview Metric Value Price (as of Friday) $66.61 Market capitalization $2.25 billion Revenue (TTM) $55.63 million Net income (TTM) ($158.10 million) ## Company snapshot - Nektar develops biopharmaceutical products targeting unmet medical needs, with a pipeline including Bempegaldesleukin (IL-2 pathway agonist), NKTR-358 (cytokine Treg stimulant), and NKTR-255 (IL-15 receptor agonist), among others. - The firm operates a research-driven business model focused on drug discovery, clinical development, and strategic collaborations with major pharmaceutical companies to generate revenue through licensing, milestones, and potential product sales. - It serves healthcare providers, hospitals, and pharmaceutical partners, targeting patients with cancer, autoimmune, and inflammatory diseases in the United States and international markets. Nektar Therapeutics is a biotechnology company specializing in the development of novel therapeutics for oncology and immunology indications. The company leverages proprietary drug discovery platforms and strategic partnerships to advance a diverse clinical pipeline. Its focus on innovative biologics and collaborative R&D positions it to address significant unmet needs in the global healthcare market. ## What this transaction means for investors Nektar stock has already delivered eye-popping gains over the past year, yet Prosight still chose to add to what has become its largest disclosed position. With that in mind, the purchase ultimately looks like a vote of confidence in Nektar as it approaches a make-or-break stretch of clinical development. Meanwhile, the core story remains rezpegaldesleukin, Nektar's experimental treatment for autoimmune diseases. Management recently reported encouraging long-term data in both atopic dermatitis and alopecia areata and expects to begin its Phase 3 ZENITH-AD program by July. The company also plans an End-of-Phase 2 meeting with the FDA for alopecia areata this quarter. Financially, Nektar appears far better positioned than many clinical-stage biotech peers. First-quarter revenue rose to $10.9 million from $10.5 million one year prior, while cash and marketable securities reached $731.6 million at quarter-end. Management noted that the figure excludes roughly $351 million of net proceeds from an April stock offering, giving the company more than $1 billion in liquidity to fund development. Ultimately, if rezpegaldesleukin succeeds in late-stage trials, today's valuation could look conservative, but if it stumbles, much of the recent rally could quickly unwind. Prosight's purchase suggests it believes the odds favor the former. ## Should you buy stock in Nektar Therapeutics right now? Before you buy stock in Nektar Therapeutics, consider this: The _Motley Fool Stock Advisor_ analyst team just identified what they believe are the **10 best stocks** for investors to buy now… and Nektar Therapeutics wasn’t one of them. The 10 stocks that made the cut could produce monster returns in the coming years. Consider when **Netflix** made this list on December 17, 2004... if you invested $1,000 at the time of our recommendation, **you’d have $477,813**!\* Or when **Nvidia** made this list on April 15, 2005... if you invested $1,000 at the time of our recommendation, **you’d have $1,320,088**!\* Now, it’s worth noting _Stock Advisor’s_ total average return is 986% — a market-crushing outperformance compared to 208% for the S&P 500. **Don't miss the latest top 10 list, available with _Stock Advisor_, and join an investing community built by individual investors for individual investors.** See the 10 stocks » _\*Stock Advisor returns as of May 23, 2026._ _Jonathan Ponciano has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy._ The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. ### Related Stocks - [NKTR.US](https://longbridge.com/en/quote/NKTR.US.md) - [FBT.US](https://longbridge.com/en/quote/FBT.US.md) - [LABU.US](https://longbridge.com/en/quote/LABU.US.md) - [BIB.US](https://longbridge.com/en/quote/BIB.US.md) - [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md) - [IBB.US](https://longbridge.com/en/quote/IBB.US.md) - [XBI.US](https://longbridge.com/en/quote/XBI.US.md) - [PBE.US](https://longbridge.com/en/quote/PBE.US.md) - [BBH.US](https://longbridge.com/en/quote/BBH.US.md) - [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md) - [.SPX.US](https://longbridge.com/en/quote/.SPX.US.md) - [BSX.US](https://longbridge.com/en/quote/BSX.US.md) - [JANX.US](https://longbridge.com/en/quote/JANX.US.md) - [PRCT.US](https://longbridge.com/en/quote/PRCT.US.md) - [LKFN.US](https://longbridge.com/en/quote/LKFN.US.md) ## Related News & Research - [Is Nektar (NKTR) Betting Its Immunology Future on Rezpegaldesleukin’s Ambitious ZENITH-AD Phase 3 Program?](https://longbridge.com/en/news/289087155.md) - [Nektar Therapeutics Launches $150 Million ATM Equity Program With Guggenheim and H.C. Wainwright](https://longbridge.com/en/news/285777430.md) - [Nektar to Announce Financial Results for the First Quarter on Thursday, May 7, 2026, After Close of U.S.-Based Financial Markets | NKTR Stock News](https://longbridge.com/en/news/284455709.md) - [45,042 Shares in Nektar Therapeutics $NKTR Bought by Readystate Asset Management LP](https://longbridge.com/en/news/276208972.md) - [BUZZ-Nektar starts $250 mln stock offering after alopecia treatment trial](https://longbridge.com/en/news/283401794.md)